PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1
Enrolling By Invitation
18 years - 99 years
All
Phase
1
15 participants needed
1 Location
Brief description of study
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: myeloma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 826672
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
